No Data
MiNK Therapeutics Rocked by Fresh Insider Share Sale
MiNK Therapeutics Announces Its Virtual 2026 Annual Shareholders Meeting
MiNK Therapeutics Shares Are Trading Higher. The Company Announced That the First Patient Has Been Dosed in Its Randomized Phase 2 Clinical Trial Evaluating AgenT-797 With Standard of Care Vs Placebo With SOC in Patients With Severe Acute Lung Injury...
MiNK Therapeutics Announces First Patient Dosed In Randomized Phase 2 Clinical Trial Evaluating Agent-797 With SOC Vs Placebo With SOC In Patients With Severe Acute Lung Injury And Critical Illness
Express News | Mink Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of Agent-797 in Acute Lung Injury and Critical Illness
MiNK Therapeutics Reports New Data on AgenT-797, an Allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications